- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Juvenile idiopathic arthritis; Severe crohn’s disease; Refractory fistulising crohn’s disease; moderate to severe hidradenitis suppurativa
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 802KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 43KB)
Adalimumab – July 2020
Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima®
Last updated
30 October 2020